Henry Schein (NASDAQ:HSIC – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 4.880-4.960 for the period, compared to the consensus EPS estimate of 4.820. The company issued revenue guidance of $13.1 billion-$13.2 billion, compared to the consensus revenue estimate of $13.0 billion.
Analyst Ratings Changes
A number of equities analysts have recently commented on HSIC shares. Wall Street Zen lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company raised their price objective on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday. Baird R W cut shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $72.00 price target (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $76.08.
Read Our Latest Stock Report on Henry Schein
Henry Schein Stock Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The company had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, sell-side analysts expect that Henry Schein will post 4.74 earnings per share for the current year.
Institutional Investors Weigh In On Henry Schein
Several institutional investors and hedge funds have recently made changes to their positions in the company. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein in the second quarter worth $25,000. Headlands Technologies LLC acquired a new position in shares of Henry Schein during the second quarter valued at $127,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein during the second quarter valued at $27,000. Captrust Financial Advisors grew its holdings in Henry Schein by 61.9% during the second quarter. Captrust Financial Advisors now owns 6,180 shares of the company’s stock worth $451,000 after acquiring an additional 2,364 shares during the period. Finally, Zuckerman Investment Group LLC boosted its position in shares of Henry Schein by 3.8% in the 2nd quarter. Zuckerman Investment Group LLC now owns 209,299 shares of the company’s stock valued at $15,289,000 after purchasing an additional 7,660 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Stories
- Five stocks we like better than Henry Schein
- Transportation Stocks Investing
- Can Gold Mining Stocks Shine as the Metals Rally Falters?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Dutch Bros Beats Earnings for 11th Consecutive Quarter
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
